Literature DB >> 15910888

Blood pressure regulation by endocannabinoids and their receptors.

Pál Pacher1, Sándor Bátkai, George Kunos.   

Abstract

Cannabinoids and their endogenous and synthetic analogs exert powerful hypotensive and cardiodepressor effects by complex mechanisms involving direct and indirect effects on myocardium and vasculature. On the one hand, endocannabinoids and cannabinoid receptors have been implicated in the hypotensive state associated with hemorrhagic, endotoxic and cardiogenic shock, and advanced liver cirrhosis. On the other hand, there is emerging evidence suggesting that the endocannabinergic system plays an important role in the cardiovascular regulation in hypertension. This review is aimed to discuss the in vivo hypotensive and cardiodepressant effects of cannabinoids mediated by cannabinoid and TRPV(1) receptors, and focuses on the novel therapeutical strategies offered by targeting the endocannabinoid system in the treatment of hypertension.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15910888      PMCID: PMC2225528          DOI: 10.1016/j.neuropharm.2004.12.005

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  57 in total

1.  Endocannabinoids as mediators in the heart: a potential target for therapy of remodelling after myocardial infarction?

Authors:  C Robin Hiley; William R Ford
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

2.  Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors.

Authors:  Sándor Bátkai; Pál Pacher; Zoltán Járai; Jens A Wagner; George Kunos
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-04-01       Impact factor: 4.733

3.  Anandamide-induced depressor effect in spontaneously hypertensive rats: role of the vanilloid receptor.

Authors:  Jianping Li; Norbert E Kaminski; Donna H Wang
Journal:  Hypertension       Date:  2002-12-30       Impact factor: 10.190

4.  Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery.

Authors:  W-S Vanessa Ho; C Robin Hiley
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

5.  CB(1) cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction.

Authors:  Jens A Wagner; Kai Hu; Jan Karcher; Johann Bauersachs; Andreas Schäfer; Martin Laser; Hong Han; Georg Ertl
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

Review 6.  Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling.

Authors:  C Robin Hiley; William R Ford
Journal:  Biol Rev Camb Philos Soc       Date:  2004-02

7.  Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA).

Authors:  Saoirse E O'Sullivan; David A Kendall; Michael D Randall
Journal:  Br J Pharmacol       Date:  2004-02-09       Impact factor: 8.739

Review 8.  Cannabinoids and neuroinflammation.

Authors:  Lisa Walter; Nephi Stella
Journal:  Br J Pharmacol       Date:  2004-02-02       Impact factor: 8.739

9.  Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  J Physiol       Date:  2004-04-30       Impact factor: 5.182

10.  G protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a Ca2+-dependent K+ current.

Authors:  Malcolm Begg; Fong-Ming Mo; László Offertaler; Sándor Bátkai; Pál Pacher; Raj K Razdan; David M Lovinger; George Kunos
Journal:  J Biol Chem       Date:  2003-09-02       Impact factor: 5.157

View more
  31 in total

Review 1.  Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications.

Authors:  Graziela Z Kalil; William G Haynes
Journal:  Hypertens Res       Date:  2011-11-03       Impact factor: 3.872

2.  Cirrhotic cardiomyopathy: an endocannabinoid connection?

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

Review 3.  Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.

Authors:  P Pacher; G Haskó
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

4.  Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis.

Authors:  Mohanraj Rajesh; Hao Pan; Partha Mukhopadhyay; Sándor Bátkai; Douglas Osei-Hyiaman; György Haskó; Lucas Liaudet; Bin Gao; Pál Pacher
Journal:  J Leukoc Biol       Date:  2007-07-25       Impact factor: 4.962

5.  Reader's response to "Endocannabinoids--the brain's own marijuana--may be linked to the metabolic syndrome".

Authors:  Paul Armentano
Journal:  MedGenMed       Date:  2006

6.  Activation of the peripheral endocannabinoid system in human obesity.

Authors:  Stefan Engeli; Jana Böhnke; Mareike Feldpausch; Kerstin Gorzelniak; Jürgen Janke; Sándor Bátkai; Pál Pacher; Judy Harvey-White; Friedrich C Luft; Arya M Sharma; Jens Jordan
Journal:  Diabetes       Date:  2005-10       Impact factor: 9.461

Review 7.  Remote neurodegeneration: multiple actors for one play.

Authors:  Maria Teresa Viscomi; Marco Molinari
Journal:  Mol Neurobiol       Date:  2014-01-19       Impact factor: 5.590

Review 8.  The emerging role of the endocannabinoid system in cardiovascular disease.

Authors:  Pál Pacher; Sabine Steffens
Journal:  Semin Immunopathol       Date:  2009-04-09       Impact factor: 9.623

9.  Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions.

Authors:  V E Mendizábal; E Adler-Graschinsky
Journal:  Br J Pharmacol       Date:  2007-04-23       Impact factor: 8.739

Review 10.  Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists.

Authors:  Helen Butler; Márta Korbonits
Journal:  Eur J Endocrinol       Date:  2009-09-03       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.